前列腺原发肿瘤立体定向体部放疗后2周巨噬细胞与CD8 T细胞密度显著变化
本研究在前列腺癌根治性前列腺切除术前给予立体定向体部放疗(SBRT),于SBRT前和SBRT后2周采用多重免疫荧光检测肿瘤内T细胞和巨噬细胞标志物,按细胞密度和像素密度分析。结果显示SBRT后2周CD68和CD163巨噬细胞显著增加,而CD8 T细胞减少,表明SBRT明显改变前列腺癌内免疫环境。
要点
- SBRT后2周前列腺癌内CD68和CD163巨噬细胞显著增加。
- SBRT后2周前列腺癌内CD8 T细胞显著减少。
- SBRT明显改变前列腺癌内的免疫环境。
核心结论
- SBRT后2周前列腺癌内CD68和CD163巨噬细胞显著增加而CD8 T细胞减少,SBRT明显改变前列腺癌内免疫环境。
研究设计与样本
- 作为SBRT新辅助根治性前列腺切除术临床试验的一部分,对前列腺癌在SBRT前和SBRT后2周采用靶向多种T细胞和巨噬细胞标志物的多重免疫荧光检测,并按细胞密度和像素密度分析。
主要发现
- SBRT后2周CD68巨噬细胞显著增加。
- SBRT后2周CD163巨噬细胞显著增加。
- SBRT后2周CD8 T细胞减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients. METHODS: Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy. RESULTS: Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.
引用
- Kane N, Romero T, Diaz-Perez S, et al. Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer Prostatic Dis. 2022. PMID: 35058580. doi:10.1038/s41391-022-00498-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。